Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-021-03817-4 http://scihub22266oqcxt.onion/10.1038/s41586-021-03817-4 34280951!9341430!34280951     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2021 ; 597 (7874): 103-108 Nephropedia Template TP {{tp|p=34280951|t=2021. Broad sarbecovirus neutralization by a human monoclonal antibody |pdf=|usr=}}{{34280951}} gab.com Text Broad sarbecovirus neutralization by a human monoclonal antibody JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=34280951 #FOAvip The recent emergence of SARS-CoV-2 variants of concern(1-10) and the recurrent spillovers of coronaviruses(11,12) into the human population highlight the need for broadly neutralizing antibodies that are not affected by the ongoing antigenic drift and that can prevent or treat future zoonotic infections. Here we describe a human monoclonal antibody designated S2X259, which recognizes a highly conserved cryptic epitope of the receptor-binding domain and cross-reacts with spikes from all clades of sarbecovirus. S2X259 broadly neutralizes spike-mediated cell entry of SARS-CoV-2, including variants of concern (B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429), as well as a wide spectrum of human and potentially zoonotic sarbecoviruses through inhibition of angiotensin-converting enzyme 2 (ACE2) binding to the receptor-binding domain. Furthermore, deep-mutational scanning and in vitro escape selection experiments demonstrate that S2X259 possesses an escape profile that is limited to a single substitution, G504D. We show that prophylactic and therapeutic administration of S2X259 protects Syrian hamsters (Mesocricetus auratus) against challenge with the prototypic SARS-CoV-2 and the B.1.351 variant of concern, which suggests that this monoclonal antibody is a promising candidate for the prevention and treatment of emergent variants and zoonotic infections. Our data reveal a key antigenic site that is targeted by broadly neutralizing antibodies and will guide the design of vaccines that are effective against all sarbecoviruses. Twit Text FOAVip Broad sarbecovirus neutralization by a human monoclonal antibody ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=34280951 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34280951 #FOAvip English Wikipedia <ref>{{Cite pmid|34280951}}</ref> Broad sarbecovirus neutralization by a human monoclonal antibody #MMPMID34280951 Tortorici MA; Czudnochowski N; Starr TN; Marzi R; Walls AC; Zatta F; Bowen JE; Jaconi S; Di Iulio J; Wang Z; De Marco A; Zepeda SK; Pinto D; Liu Z; Beltramello M; Bartha I; Housley MP; Lempp FA; Rosen LE; Dellota E Jr; Kaiser H; Montiel-Ruiz M; Zhou J; Addetia A; Guarino B; Culap K; Sprugasci N; Saliba C; Vetti E; Giacchetto-Sasselli I; Fregni CS; Abdelnabi R; Foo SC; Havenar-Daughton C; Schmid MA; Benigni F; Cameroni E; Neyts J; Telenti A; Virgin HW; Whelan SPJ; Snell G; Bloom JD; Corti D; Veesler D; Pizzuto MS Nature 2021[Sep]; 597 (7874): 103-108 PMID34280951show ga The recent emergence of SARS-CoV-2 variants of concern(1-10) and the recurrent spillovers of coronaviruses(11,12) into the human population highlight the need for broadly neutralizing antibodies that are not affected by the ongoing antigenic drift and that can prevent or treat future zoonotic infections. Here we describe a human monoclonal antibody designated S2X259, which recognizes a highly conserved cryptic epitope of the receptor-binding domain and cross-reacts with spikes from all clades of sarbecovirus. S2X259 broadly neutralizes spike-mediated cell entry of SARS-CoV-2, including variants of concern (B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429), as well as a wide spectrum of human and potentially zoonotic sarbecoviruses through inhibition of angiotensin-converting enzyme 2 (ACE2) binding to the receptor-binding domain. Furthermore, deep-mutational scanning and in vitro escape selection experiments demonstrate that S2X259 possesses an escape profile that is limited to a single substitution, G504D. We show that prophylactic and therapeutic administration of S2X259 protects Syrian hamsters (Mesocricetus auratus) against challenge with the prototypic SARS-CoV-2 and the B.1.351 variant of concern, which suggests that this monoclonal antibody is a promising candidate for the prevention and treatment of emergent variants and zoonotic infections. Our data reveal a key antigenic site that is targeted by broadly neutralizing antibodies and will guide the design of vaccines that are effective against all sarbecoviruses. |Animals[MESH] |Antibodies, Monoclonal/chemistry/*immunology/*therapeutic use[MESH] |Antibodies, Viral/chemistry/*immunology/therapeutic use[MESH] |Broadly Neutralizing Antibodies/chemistry/*immunology/*therapeutic use[MESH] |COVID-19/immunology/*prevention & control/virology[MESH] |Cross Reactions/immunology[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Humans[MESH] |Immune Evasion/genetics/immunology[MESH] |Mesocricetus/immunology/virology[MESH] |Mutation[MESH] |Neutralization Tests[MESH] |SARS-CoV-2/chemistry/*classification/genetics/*immunology[MESH]Broad sarbecovirus neutralization by a human monoclonal antibody (epmc).pdf DeepDyve Pubget Overpricing